# Belite Bio, Inc (BLTE)

> Source: Nexqual · https://nexqual.com/BLTE · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Belite Bio, Inc (BLTE), nexqual.com/BLTE" · informational, not investment advice.

**Price:** USD 152.62 (-0.07% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 152.72 · day 152.13–155.47 · 52w 81.01–200 · market cap $6.15B · NCM

## Key facts
- 1 of 80 tracked superinvestors hold BLTE (13F, Q2 2026): 1 new, 0 added, 0 reduced, 0 unchanged.
- Analysts: Buy (mean 1.78 on a 1–5 scale) (9 analysts), mean target USD 228.89 (range 185–303).
- Total return with dividends: 1Y +71.3% vs S&P 500 +18.1%; 5Y +1341.2% vs S&P 500 +85.1%.
- Next earnings: 2026-11-09, EPS estimate USD -0.77, revenue estimate $0K.

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold BLTE. Change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Lee Ainslie | Maverick Capital | 0.55% | $61.0M | New position |

## Analysts
Consensus Buy (mean 1.78 on a 1–5 scale), 9 analysts; mean target USD 228.89 (low 185, high 303).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-15 | HC Wainwright & Co. | Reiterated | Buy | $245 |
| 2026-09-09 | Mizuho | Target raised | Outperform | $220 → $234 |
| 2026-09-08 | HC Wainwright & Co. | Target raised | Buy | $214 → $245 |
| 2026-09-04 | Canaccord Genuity | Initiated | Buy | $303 |
| 2026-08-14 | Morgan Stanley | Target raised | Overweight | $201 → $206 |
| 2026-08-14 | Cantor Fitzgerald | Target raised | Overweight | $266 → $270 |
| 2026-08-12 | HC Wainwright & Co. | Target raised | Buy | $200 → $214 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2022-04-25) |
|---|---|---|
| Total return | +71.3% | +1341.2% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +71.7% | +81.5% |
| Volatility (annualized) | 53.1% | 68.6% |
| Max drawdown | -29.1% (Feb 2026→Jun 2026) | -74.0% (Jul 2022→Jun 2023) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44% · ABVX (Abivax SA) USD 92.38 +7.14%

## More
Full page: https://nexqual.com/BLTE · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt